$60.97−2.52 (−3.97%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
PTC Therapeutics (PTCT) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Jun 30, 2026*. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 385 filers, Jun 30, 2026
# 13F FUNDS
385
13F VALUE
$8.3B
101.4M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 2,118 | $59.52 | ↗ |
| Oct 14, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 382 | $60.14 | ↗ |
| Oct 9, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Acquired · Option exercise | 192 | $39.42 | ↗ |
| Oct 9, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Open-market sale | 192 | $64.26 | ↗ |
| Oct 9, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Option exercise | 192Stock Option (Right to Buy) | — | ↗ |
| Oct 7, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 2,447 | $63.38 | ↗ |
| Oct 7, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 53 | $63.95 | ↗ |
| Oct 6, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Acquired · Option exercise | 435 | $39.42 | ↗ |
| Oct 6, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Open-market sale | 435 | $64.16 | ↗ |
| Oct 6, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Option exercise | 435Stock Option (Right to Buy) | — | ↗ |
| Oct 5, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Acquired · Option exercise | 1,638 | $39.42 | ↗ |
| Oct 5, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Open-market sale | 1,638 | $64.03 | ↗ |
| Oct 5, 2026 | Boulding Mark Elliott | EXEC. VP AND CLO | Disposed · Option exercise | 1,638Stock Option (Right to Buy) | — | ↗ |
| Sep 30, 2026 | STEELE GLENN JR MD PHD | director | Acquired · Option exercise | 12,000 | $11.23 | ↗ |
| Sep 30, 2026 | STEELE GLENN JR MD PHD | director | Disposed · Open-market sale | 12,000 | $65.16 | ↗ |
| Sep 30, 2026 | STEELE GLENN JR MD PHD | director | Disposed · Option exercise | 12,000Stock Option (Right to Buy) | — | ↗ |
| Sep 17, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 9,624 | $67.83 | ↗ |
| Sep 17, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 376 | $68.45 | ↗ |
| Sep 16, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 2,994 | $66.58 | ↗ |
| Sep 16, 2026 | SCHMERTZLER MICHAEL | director | Disposed · Open-market sale | 7,006 | $67.35 | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold PTC Therapeutics?
PTC Therapeutics was held by 385 13F filers as of Jun 30, 2026.
Not investment advice.

